BIOMAT Database Logo BIOMAT Database Logo

Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands. 1997

M M Herremans, and A M van Loon, and J H Reimerink, and H C Rümke, and H G van der Avoort, and T G Kimman, and M P Koopmans
Research Laboratory for Infectious Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands. Tineke.Herremans@rivm.nl

In The Netherlands the inactivated poliovirus vaccine (IPV) is used for protection against poliomyelitis. It is not clear if parenteral vaccination with IPV can lead to priming of the mucosal immune system. We developed and evaluated enzyme-linked immunosorbent assays for the detection of poliovirus serotype-specific immunoglobulin A (IgA) and secretory IgA antibodies. Using these assays we examined the kinetics of the IgA response in sequential serum samples from 15 poliomyelitis patients after natural infection with serotype 3 poliovirus. In 36% of the patients IgA remained present for up to 5 months postinfection. Furthermore, we examined, in an IPV-vaccinated population, the presence of IgA antibodies in sera from young children (4 to 12 years of age; n = 177), sera from older children (between 13 and 15 years of age; n = 123), sera from healthy blood donors (n = 66), and sera from naturally immune elderly persons (n = 54). The seroprevalence of IgA to all three serotypes was low in young vaccinated children (5 to 7%), and the seroprevalence of IgA types 2 and 3 was low in older vaccinated children (2 to 3%). The seroprevalence of antibodies to type 1 was significantly higher (18%) in older children than in younger children. This higher seroprevalence is most likely explained by the persistence of IgA following infection with the serotype 1 wild-type poliovirus strain during the 1978 epidemic. In healthy adults, the seroprevalence of type 1- and type 2-specific IgA was significantly higher than that in young children. These results suggest that at least part of the IgA found in the older population is induced by infections unrelated to the IPV vaccination schedule. Finally, we found that parenteral vaccination with IPV was able to boost secretory IgA responses in 74 to 87% of a naturally exposed elderly population (n = 54). While the presence of secretory IgA in IPV-vaccinated persons has been documented previously, our findings suggest that mucosal priming with live virus is necessary to obtain an IgA response after IPV booster vaccination.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007223 Infant A child between 1 and 23 months of age. Infants
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009426 Netherlands Country located in EUROPE. It is bordered by the NORTH SEA, BELGIUM, and GERMANY. Constituent areas are Aruba, Curacao, and Sint Maarten, formerly included in the NETHERLANDS ANTILLES. Holland,Kingdom of the Netherlands
D011051 Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5) Infantile Paralysis,Polio,Poliomyelitis, Nonpoliovirus,Poliomyelitis, Preparalytic,Encephalitis, Polio,Epidemic Acute Poliomyelitis,Polio Encephalitis,Poliomyelitis Infection,Poliomyelitis, Acute,Acute Poliomyelitis,Acute Poliomyelitis, Epidemic,Infection, Poliomyelitis,Infections, Poliomyelitis,Nonpoliovirus Poliomyelitis,Paralysis, Infantile,Poliomyelitides, Preparalytic,Poliomyelitis Infections,Poliomyelitis, Epidemic Acute,Polios,Preparalytic Poliomyelitis
D011054 Poliovirus Vaccine, Inactivated A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS. Salk Vaccine,Inactivated Poliovirus Vaccine,Vaccine, Inactivated Poliovirus,Vaccine, Salk
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children

Related Publications

M M Herremans, and A M van Loon, and J H Reimerink, and H C Rümke, and H G van der Avoort, and T G Kimman, and M P Koopmans
[Neutralizing antibodies in the sera of persons vaccinated with intradermal poliovirus vaccine].
January 1984, Przeglad epidemiologiczny,
M M Herremans, and A M van Loon, and J H Reimerink, and H C Rümke, and H G van der Avoort, and T G Kimman, and M P Koopmans
Inactivated poliovirus vaccine.
January 2007, Human vaccines,
M M Herremans, and A M van Loon, and J H Reimerink, and H C Rümke, and H G van der Avoort, and T G Kimman, and M P Koopmans
[Inactivated poliovirus vaccine].
September 2011, Nihon rinsho. Japanese journal of clinical medicine,
M M Herremans, and A M van Loon, and J H Reimerink, and H C Rümke, and H G van der Avoort, and T G Kimman, and M P Koopmans
Evaluating the cost per child vaccinated with full versus fractional-dose inactivated poliovirus vaccine.
August 2019, Vaccine: X,
M M Herremans, and A M van Loon, and J H Reimerink, and H C Rümke, and H G van der Avoort, and T G Kimman, and M P Koopmans
Effect of a single dose of oral poliovirus vaccine in persons previously immunized with inactivated vaccine.
June 1962, British medical journal,
M M Herremans, and A M van Loon, and J H Reimerink, and H C Rümke, and H G van der Avoort, and T G Kimman, and M P Koopmans
Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark.
January 1984, Reviews of infectious diseases,
M M Herremans, and A M van Loon, and J H Reimerink, and H C Rümke, and H G van der Avoort, and T G Kimman, and M P Koopmans
Inactivated poliovirus vaccine following oral poliovirus vaccine cessation.
April 2006, Releve epidemiologique hebdomadaire,
M M Herremans, and A M van Loon, and J H Reimerink, and H C Rümke, and H G van der Avoort, and T G Kimman, and M P Koopmans
Enhanced inactivated poliovirus vaccine.
July 1994, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses,
M M Herremans, and A M van Loon, and J H Reimerink, and H C Rümke, and H G van der Avoort, and T G Kimman, and M P Koopmans
Polio myelitis in subjects vaccinated with inactivated poliovirus. A preliminary report.
March 1961, Panminerva medica,
M M Herremans, and A M van Loon, and J H Reimerink, and H C Rümke, and H G van der Avoort, and T G Kimman, and M P Koopmans
Inactivated poliovirus vaccine in Finland.
January 1984, Reviews of infectious diseases,
Copied contents to your clipboard!